Encapsulation of Pseudomonas aeruginosa strain KBN12 decolourizes and bioremediates brilliant blue dye mediated toxicity in mung bean (Vigna radiata L.).

AIM: The aim of this study was to explore the decolourization and bioremediation ability of non-encapsulated and encapsulated Pseudomonas aeruginosa (strain KBN 12) against the azo dye brilliant blue (BB). METHODS AND RESULTS: Six efficient BB dye-decolourizing bacteria were isolated from textile dye effluent. The most efficient free cells of P. aeruginosa KBN 12 along with the optimized conditions such as carbon source (maltose: 5 g L-1), and nitrogen source (ammonium chloride: 4 g L-1) at pH 6 at 37°C decolourized 72.69% of BB dye aerobically after 9 days of incubation under static conditions. Encapsulated (calcium alginate) P. aeruginosa KBN 12 decolourized 87.67% of BB dye aerobically after 9 days of incubation under the same optimized conditions. Fourier-transform infrared spectroscopy (FTIR) and gas chromatography (GC) analysis of the chemical structure of BB dye after decolourization found changes in functional and chemical groups. Phytotoxicity and soil respiration enzyme assays revealed that the decolourized dye or dye products were less toxic than the pure BB dye. CONCLUSION: The encapsulation of P. aeruginosa KBN 12 proved to be an effective method for BB dye decolourization or remediation.

Psychiatric comorbidity in depressed HIV-infected individuals: common and clinically consequential.

OBJECTIVE: To report on the prevalence of psychiatric comorbidity and its association with illness severity in depressed HIV patients. METHODS: As part of a multi-site randomized controlled trial of depression treatment for HIV patients, 304 participants meeting criteria for current Major Depressive Disorder (MDD) were assessed for other mood, anxiety and substance use disorders with the Mini-International Neuropsychiatric Interview, a structured psychiatric diagnostic interview. We also assessed baseline adherence, risk, and health measures. RESULTS: Complicated depressive illness was common. Only 18% of participants experienced MDD with no comorbid psychiatric diagnoses; 49% had comorbid dysthymia, 62% had ≥1 comorbid anxiety disorder, and 28% had a comorbid substance use disorder. Self-reported antiretroviral adherence did not differ by the presence of psychiatric comorbidity. However, psychiatric comorbidity was associated with worse physical health and functioning: compared to those with MDD alone, individuals with ≥1 comorbidity reported more HIV symptoms (5.1 vs. 4.1, P=.01), and worse mental health-related quality of life on the SF-12 (29 vs. 35, P<.01). CONCLUSION: For HIV patients with MDD, chronic depression and psychiatric comorbidity are strikingly common, and this complexity is associated with greater HIV disease severity and worse quality of life. Appreciating this comorbidity can help clinicians better target those at risk of harder-to-treat HIV disease, and underscores the challenge of treating depression in this population.